New monoclonal antibodies targeting IL-6
Written by: Jonathan Simmons | Last reviewed: September 2013.
1. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013;5:1-4. 2. Clinicaltrials.gov. 3. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011;23:245-51. 4. Woodrick RS, Ruderman EM. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. Bull NYU Hosp Jt Dis 2012;70:195-9. 5. Sanofi and Regeneron announce patient enrollment in two Phase 3 trials with sarilumab in rheumatoid arthritis (RA). Regeneron press release; May 15, 2013. 6. Interleukin-6 inhibitor sirukumab (CNTO 136) phase 2 data show promise in the treatment of active rheumatoid arthritis. Medical News Today. May 25, 2011. 7. Janssen announces initiation of phase 3 development program for sirukumab in rheumatoid arthritis. Janssen Research & Development, LLC Press Release; August 23, 2012. 8. Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Annals of the Rheumatic Diseases 2012;71:1183-9.